Key results
The company
Novo Nordisk
novonordisk.comPharmaceutical company specializing in diabetes, obesity, and rare blood disorders.
Result highlights
- Potential $157M net new value over 5 years
- Potential $14M efficiency gains over 5 years
- Insight generation cut from weeks to seconds
The story
A century-old global pharmaceutical leader focused on diabetes and chronic diseases, managing billions of clinical trial data points across highly regulated environments.
A "patchwork spiderweb" of siloed systems forced teams to manually pass information between departments, creating bottlenecks in clinical trial research. Critical data was trapped in individual storage solutions, preventing the scaling of AI initiatives and complicating regulatory compliance.
The organization implemented a hybrid Data Mesh architecture on Databricks, allowing research domains to own their data while enforcing unified governance through Unity Catalog. They deployed "Co-Scientist" AI agents that enable staff to query clinical data via natural language to identify adverse events and trial protocols. The platform integrates Terraform and Azure DevOps to ensure standardized, reproducible workflows across 60+ production teams.
Scope & timeline
- 9 months from concept to MVP
- 1,000 active users on data platform
- 20% developer adoption of clinical data
Quotes
“We’re at a crossroads of democratizing data access to a wider number of people so that insights can be leveraged by more. Before Databricks, it was difficult to provide this level of access. Databricks offers the infrastructure necessary to unlock the full potential of our data-driven initiatives.”